Andrew A. Protter

7.5k total citations · 1 hit paper
80 papers, 6.0k citations indexed

About

Andrew A. Protter is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Andrew A. Protter has authored 80 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 22 papers in Cardiology and Cardiovascular Medicine and 16 papers in Oncology. Recurrent topics in Andrew A. Protter's work include Melanoma and MAPK Pathways (13 papers), Heart Failure Treatment and Management (12 papers) and Peptidase Inhibition and Analysis (7 papers). Andrew A. Protter is often cited by papers focused on Melanoma and MAPK Pathways (13 papers), Heart Failure Treatment and Management (12 papers) and Peptidase Inhibition and Analysis (7 papers). Andrew A. Protter collaborates with scholars based in United States, New Zealand and United Kingdom. Andrew A. Protter's co-authors include Roger White, Lawrence W. Stanton, Gerda Endemann, Kelley S. Madden, Ann M. Kapoun, George F. Schreiner, Andrew Lam, Satyanarayana Medicherla, Sarvajit Chakravarty and Sundeep Dugar and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Andrew A. Protter

79 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD36 is a receptor for oxidized low density lipoprotein

1993 1.1k citations Andrew A. Protter et al. profile →

Peers

Countries citing papers authored by Andrew A. Protter

Since Specialization

Citations

This map shows the geographic impact of Andrew A. Protter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew A. Protter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew A. Protter more than expected).

Fields of papers citing papers by Andrew A. Protter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew A. Protter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew A. Protter. The network helps show where Andrew A. Protter may publish in the future.

Co-authorship network of co-authors of Andrew A. Protter

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew A. Protter. A scholar is included among the top collaborators of Andrew A. Protter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew A. Protter. Andrew A. Protter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma 2017 ·Molecular Cancer Therapeutics ·Sani H. Kizilbash, Shiv K. Gupta, Kenneth Tou En Chang, (unknown), Karen E. Parrish, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Gaspar J. Kitange, Yuqiao Shen, Ying Feng, Andrew A. Protter, William F. Elmquist, Jann N. Sarkaria	60
2	Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR) 2017 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Pradeep S. Jadhavar, (unknown), (unknown), (unknown), Kevin P. Quinn, Po‐yin Anne Wong, Andrew A. Protter, Roopa Rai, Son M. Pham, Jeffrey N. Lindquist	8
3	Novel p38α Mitogen‐Activated Protein Kinase Inhibitor Shows Analgesic Efficacy in Acute Postsurgical Dental Pain 2011 ·The Journal of Clinical Pharmacology ·Sandra Tong, Stephen E. Daniels, Peter M. Black, Stephen Chang, Andrew A. Protter, Paul J. Desjardins	32
4	Long-term Effects of B-type Natriuretic Peptide Infusion After Acute Myocardial Infarction in a Rat Model 2010 ·Journal of Cardiovascular Pharmacology ·Isaac George, Steve Xydas, Stefan Klotz, Ilan Hay, (unknown), Jonathan S. Chang, Kai Xu, Zhihe Li, Andrew A. Protter, EX Wu, Mehmet C. Öz, Jie Wang	7
5	Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury 2009 ·American Journal of Physiology-Heart and Circulatory Physiology ·Isaac George, (unknown), Kai Xu, Geng‐Hua Yi, Jeffrey W. Holmes, EX Wu, Zhihe Li, Andrew A. Protter, Mehmet C. Öz, Jie Wang	6
6	Role of the TGF-β/Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension 2008 ·American Journal of Respiratory and Critical Care Medicine ·Ari Zaiman, Megan Podowski, Satya Medicherla, (unknown), Fang Xu, Lijie Zhen, Larissa A. Shimoda, Enid Neptune, Linda S. Higgins, Alison Murphy, Sarvajit Chakravarty, Andrew A. Protter, Pravin B. Sehgal, Hunter C. Champion, Rubin M. Tuder	115
7	Evidence for Functional Heterogeneity of Circulating B-Type Natriuretic Peptide 2007 ·Journal of the American College of Cardiology ·Faquan Liang, Jessica O’Rear, Ute Schellenberger, (unknown), (unknown), George F. Schreiner, Fred S. Apple, Alan S. Maisel, N. Stephen Pollitt, Andrew A. Protter	200
8	p38α-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway Inflammation 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Satyanarayana Medicherla, (unknown), (unknown), Paul Woodman, (unknown), Ann M. Kapoun, Sarvajit Chakravarty, Sundeep Dugar, Andrew A. Protter, Linda S. Higgins	75
9	A Selective p38α Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Satyanarayana Medicherla, Ying Jing, Ruban Mangadu, Yebin Jiang, Jenny Zhao, Ramona G. Almirez, Irene Kerr, Elizabeth G. Stebbins, Gilbert O’Young, Ann M. Kapoun, Gregory R. Luedtke, Sarvajit Chakravarty, Sundeep Dugar, Harry K. Genant, Andrew A. Protter	65
10	The precursor to B-type natriuretic peptide is an O-linked glycoprotein 2006 ·Archives of Biochemistry and Biophysics ·Ute Schellenberger, Jessica O’Rear, Andrew W. Guzzetta, Rodney A. Jue, Andrew A. Protter, N. Stephen Pollitt	127
11	Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor 2004 ·American Journal of Respiratory and Critical Care Medicine ·Philippe Bonniaud, Peter J. Margetts, Martin Kolb, (unknown), Ann M. Kapoun, Debby Damm, Alison Murphy, Sarvajit Chakravarty, Sundeep Dugar, Linda S. Higgins, Andrew A. Protter, Jack Gauldie	210
12	Fighting pulmonary fibrosis: new science brings new therapeutic opportunities 2004 ·Drug Discovery Today Therapeutic Strategies ·Anuk Das, Don E. Griswold, Christopher J. Molloy, Andrew A. Protter, Geoffrey J. Laurent	5
13	Activation of p38 mitogen‐activated protein kinase in spinal microglia is a critical link in inflammation‐induced spinal pain processing 2003 ·Journal of Neurochemistry ·Camilla I. Svensson, Martin Maršala, Anna Westerlund, Nigel A. Calcutt, W. Marie Campana, Jason D. Freshwater, Rosanne Catalano, Ying Feng, Andrew A. Protter, Brian T. Scott, Tony L. Yaksh	320
14	Examination of the in vivo cardiac electrophysiological effects of nesiritide (human brain natriuretic peptide) in conscious dogs 2002 ·Journal of Cardiac Failure ·Guilherme Fenelon, Andrew A. Protter, Bruce S. Stambler	2
15	Delayed Administration of Basic Fibroblast Growth Factor (bFGF) Attenuates Cognitive Dysfunction Following Parasagittal Fluid Percussion Brain Injury in the Rat 1997 ·Journal of Neurotrauma ·(unknown), Ramesh Raghupathi, (unknown), Kathryn E. Saatman, Andrew A. Protter, Seth P. Finklestein, Grant Sinson, Douglas H. Smith, Tracy K. McIntosh	61
16	Relaxant effect of human brain natriuretic peptide on human artery and vein tissue 1996 ·American Journal of Hypertension ·Andrew A. Protter	66
17	Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process 1987 ·Atherosclerosis ·Sven‐Olof Olofsson, Gunnar Bjursell, Kristina Bengtsson Boström, Peter Carlsson, John Elovson, Andrew A. Protter, Michael A. Reuben, Göran Bondjers	135
18	Structural comparison of human apolipoproteins B-48 and B-100 1987 ·Biochemistry ·(unknown), Andrew A. Protter, G. Chi Chen, James W. Schilling, Kevin Sato, (unknown), Miles K. Yamanaka, (unknown), Judith Miller	15
19	Isolation and DNA Sequence of Full-Length cDNA and of the Entire Gene for Human Apolipoprotein AI—Discovery of a New Genetic Polymorphism in the apo AI Gene 1984 ·DNA ·Jeffrey J. Seilhamer, Andrew A. Protter, Philippe Frossard, Beatriz Levy-Wilson	63
20	Isolation and Sequence Analysis of the Human Apolipoprotein CIII Gene and the Intergenic Region between the Apo AI and Apo CIII Genes 1984 ·DNA ·Andrew A. Protter, Beatriz Levy-Wilson, (unknown), G H Bencen, (unknown), Jeffrey J. Seilhamer	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact